Read the latest press releases from Calliditas Therapeutics by clicking on a title below.

For press enquiries please contact us.

Calliditas announces clinical development plan for setanaxib and comments on data from Part A of NefIgArd study at today´s R&D Day

Calliditas Therapeutics AB
Kungsbron 1, C8
SE-111 22 Stockholm
Sweden

Company number: 556659-9766

© Calliditas Therapeutics AB 2021